GSK announces Phase III data for TYKERB/TYVERB® (lapatinib) in combination with chemotherapy for advanced HER2-positive gastric cancer
GlaxoSmithKline (GSK) plc today announced that its study of TYKERB/TYVERB® (lapatinib) in combination with chemotherapy in patients with HER2-positive advanced gastric cancer did not meet the primary endpoint of improved overall survival (OS) compared to chemotherapy alone. (Source: GSK news)
Source: GSK news - June 3, 2013 Category: Pharmaceuticals Source Type: news
GSK announces late-stage clinical data for VOTRIENT® (pazopanib) following chemotherapy in women with advanced epithelial ovarian cancer
GlaxoSmithKline (GSK) plc today announced that its Phase III clinical trial of VOTRIENT (pazopanib) as maintenance therapy in women with advanced epithelial ovarian cancer following front-line chemotherapy met the primary objective of a statistically significant improvement in the time to disease progression or death (progression-free survival, PFS) compared to placebo. (Source: GSK news)
Source: GSK news - June 1, 2013 Category: Pharmaceuticals Source Type: news
Two new GSK oral oncology treatments, BRAF-inhibitor Tafinlar® (dabrafenib) capsules and the first MEK-inhibitor Mekinist™ (trametinib) tablets, approved by FDA as single-agent therapies
- Both approved for unresectable or metastatic melanoma with BRAF V600E mutation; Mekinist also approved for BRAF V600K mutation (Source: GSK news)
Source: GSK news - May 29, 2013 Category: Pharmaceuticals Source Type: news
GSK and Genmab announce positive top-line results from pivotal trial of ARZERRA® (ofatumumab) combined with chlorambucil in previously untreated chronic lymphocytic leukaemia
GlaxoSmithKline (GSK) plc and Genmab A/S (OMX: GEN) announced today that their Phase III study of ARZERRA® (ofatumumab) in combination with chlorambucil versus chlorambucil alone in patients with previously untreated chronic lymphocytic leukaemia (CLL) met its primary endpoint of progression free survival (PFS) as assessed by an independent review committee (IRC). (Source: GSK news)
Source: GSK news - May 29, 2013 Category: Pharmaceuticals Source Type: news
GSK strengthens vaccines business with acquisition of Okairos
GlaxoSmithKline (GSK) today announced that it has acquired Okairos AG (Okairos), a specialist developer of vaccine platform technologies for €250 million (approximately £215 million/$325 million) in cash. (Source: GSK news)
Source: GSK news - May 29, 2013 Category: Pharmaceuticals Source Type: news
Grant to Help Coordinate Campaign to Train One Million Community Health Workers in sub-Saharan Africa
In an effort to broadly expand the reach of health care services in sub-Saharan Africa, GlaxoSmithKline (GSK) will contribute $750,000 to the One Million Community Health Workers Campaign. (Source: GSK news)
Source: GSK news - May 24, 2013 Category: Pharmaceuticals Source Type: news
GlaxoSmithKline awarded up to $200 million by U.S. government to develop new antibiotics
GlaxoSmithKline (GSK) plc and the Biomedical Advanced Research and Development Authority (BARDA), have agreed to a first of its kind collaboration that will support the development of several antibiotics to fight antibiotic resistance and bioterrorism. (Source: GSK news)
Source: GSK news - May 21, 2013 Category: Pharmaceuticals Source Type: news
BREO™ ELLIPTA™ gains US approval for the treatment of COPD
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO™ ELLIPTA™ as an inhaled long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. (Source: GSK news)
Source: GSK news - May 10, 2013 Category: Pharmaceuticals Source Type: news
GSK and Save the Children form unique partnership to save the lives of one million children
An ambitious new partnership to save the lives of a million of the poorest children in the world has been launched by GSK and Save the Children. (Source: GSK news)
Source: GSK news - May 9, 2013 Category: Pharmaceuticals Source Type: news
GSK enters new commitment with the GAVI Alliance to supply cervical cancer vaccine for girls in the world’s poorest countries
GlaxoSmithKline (GSK) today announced a new commitment to the GAVI Alliance to supply its cervical cancer vaccine as part of a new long term programme to help protect girls against cervical cancer in the world’s poorest countries. (Source: GSK news)
Source: GSK news - May 9, 2013 Category: Pharmaceuticals Source Type: news
GSK gives update on plans to share detailed clinical trial data as part of its commitment to transparency
GlaxoSmithKline (GSK) today announced progress on its commitment to share more detailed data from its clinical trials. (Source: GSK news)
Source: GSK news - May 7, 2013 Category: Pharmaceuticals Source Type: news
Funding boost for GSK’s open innovation research into diseases affecting the developing world
GlaxoSmithKline plc (GSK) today announced a funding injection of up to £5m from the Wellcome Trust to support its open approach to discovering and developing urgently needed new treatments for diseases of the developing world. (Source: GSK news)
Source: GSK news - May 3, 2013 Category: Pharmaceuticals Source Type: news
Regulatory update: Trametinib US PDUFA date extended to 3 September 2013
GSK today announced that the US Prescription Drug User Fee Act (PDUFA) goal date for trametinib, its MEK inhibitor, has been extended by 3 months to 3 September 2013. (Source: GSK news)
Source: GSK news - May 1, 2013 Category: Pharmaceuticals Source Type: news
GSK announces regulatory submission for umeclidinium monotherapy in US
GlaxoSmithKline plc today announced the submission of a regulatory application in the US for the investigational once-daily medicine, umeclidinium bromide (UMEC), for patients with chronic obstructive pulmonary disease (COPD). (Source: GSK news)
Source: GSK news - April 30, 2013 Category: Pharmaceuticals Source Type: news
GlaxoSmithKline and Impax Pharmaceuticals terminate their collaboration on IPX066
GlaxoSmithKline (GSK) plc and Impax Pharmaceuticals today announced that they are terminating their collaboration for the development and commercialisation of IPX066 outside the United States and Taiwan. (Source: GSK news)
Source: GSK news - April 29, 2013 Category: Pharmaceuticals Source Type: news
